Eprosartan_Mesylate_Hydrochlorothiazide: profile and news

Kos Reports 49% Increase in Revenue to $179.4 Million, Earnings ...  Aug 4, 2005
Biovail Corporation's affiliates an exclusive license to Teveten (eprosartan mesylate) and Teveten HCT (eprosartan mesylate/hydrochlorothiazide) and obtained ... - Business Wire (press release)

Kos Announces Strategic Commercialization and Research and ...  May 3, 2005
Pursuant to the agreements, Kos acquired Teveten (eprosartan mesylate), Teveten HCT (eprosartan mesylate/hydrochlorothiazide) and obtained exclusive sales and ... - Business Wire

Kos Enters Cardio Area, Gets Biovail Products For $104M  May 3, 2005
Teveten HCT (eprosartan mesylate/hydrochlorothiazide) was launched in 2003 and combines eprosartan with a diuretic, providing large reductions in systolic ... - BioWorld Online (subscription)